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Abstract
Background: Promotion of bone regeneration is important for successful repair of bony defects. This study aimed
to investigate whether combining bone marrow-derived mesenchymal stem cell (BMSC) sheets with platelet-rich
plasma (PRP) gel/calcium phosphate particles could promote bone formation in the femoral bone defects of rats.
Methods: The proliferation and differentiation of BMSCs or BMSC sheets cultured with calcium phosphate particles
and/or PRP were investigated in in vitro. In vivo, 36 2.5 × 5 mm bone defects were randomly divided into groups
and treated with either BMSCs/PRP gel, calcium phosphate particles, PRP gel/calcium phosphate particles, a BMSC
sheet/calcium phosphate particles, a BMSC sheet/PRP gel/calcium phosphate particles, or were left untreated
(n = 6/group). A further 15 bone defects were treated with chloromethyl-benzamidodialkylcarbocyanine
(CM-Dil)-labelled BMSC sheet/PRP gel/calcium phosphate particles and observed using a small animal in vivo
fluorescence imaging system to trace the implanted BMSCs at 1 day, 3 days, 7 days, 2 weeks, and 4 weeks
after surgery.
Results: The expression of collagen type I and osteocalcin genes of BMSCs or BMSC sheets treated with PRP
and calcium phosphate particles was significantly higher than that of BMSCs or BMSC sheets treated with
calcium phosphate particles or the controls (P <0.05). PRP can promote gene expression of collagen III and
tenomodulin by BMSCs and in BMSC sheets. The VEGF, collagen I and osteocalcin gene expression levels
were higher in the BMSC sheet than in cultured BMSCs (P <0.05). Moreover, alizarin red staining quantification, ALP
quantification and calcein blue fluorescence showed the osteogenic potential of BMSCs treated with PRP and calcium
phosphate particles The implanted BMSCs were detectable at 1 day, 3 days, 7 days, 2 weeks and 4 weeks after surgery
by a small animal in vivo fluorescence imaging system and were visualized in the defect zones by confocal microscopy.
At 4 weeks after implantation, the defects treated with the BMSC sheet/PRP gel/calcium phosphate particles showed
significantly more bone formation than the other five groups.
Conclusions: Incorporation of an BMSC sheet into the PRP gel/calcium phosphate particles greatly promoted bone
regeneration. These BMSC sheet and tissue engineering strategies offer therapeutic opportunities for promoting bone
defect repair clinically.
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Background
In recent decades, tissue engineering has emerged as an
alternative and promising approach for repair of bone
defects, using bone marrow-derived mesenchymal stem
cells (BMSCs) embedded in a biocompatible scaffold or
with growth factors [1]. BMSCs are multipotential cells
that can be induced to differentiate into several meso-
dermal cell types, e.g., osteoblasts, chondrocytes, adipo-
cytes, tenocytes, and myoblasts [2]. In previous studies,
BMSCs combined with various materials have been
found to regenerate bone defects using cell suspension
systems [3–5]. However, the adhesion rate of BMSCs is
low due to the low surface-to-volume ratio of scaffolds.
The cell suspension systems have fewer advantages or
cannot be used with scaffolds of non-porous materials
or particles. To address this issue, we adopted a cell
transplantation method in which BMSCs are cultured
and lifted as a cell sheet structure. The BMSC sheet
allows delivery of a much larger number of cells to
facilitate tissue regeneration [6, 7]. In addition, the
BMSC sheet can be easily detached from the culture
substrate, while the extracellular matrix (ECM), the
adhesion molecules on the cell surface, and cell-cell
interactions remain intact [8].
Among the biomaterials used for bone defect repair,
CaP scaffolds have been widely used due to their resem-
blance to the inorganic composition of bone and have
demonstrated excellent biocompatibility and osteocon-
duction [9–11]. However, it is difficult to use Cap blocks
to fill irregularly shaped bone defects [12, 13], and the
surgeon must often machine the graft or carve into the
surgical site, which increases bone loss, trauma, and sur-
gical time [14]. CaP particles are generally preferred for
filling bone defects; however, they are difficult to handle
and to maintain in the defects, leading to empty spaces
between the particles and bone tissue with mechanical
instability [14].
To improve the osteogenic potential of scaffolds,
growth factors are usually introduced. Platelet-rich
plasma (PRP), which can be easily obtained from blood,
is a natural source of growth factors, including platelet-
derived growth factor (PDGF), transforming growth fac-
tor (TGF-β1, TGF-β2), insulin-like growth factor (IGF-1,
IGF-2), and vascular endothelial growth factor (VEGF)
[15]. PRP can be activated by thrombin to form PRP gel.
In addition, the adhesive properties of PRP gel make
possible moulding of CaP particles into even complex
bone defects.
The CaP particles and PRP gel were further wrapped
by a BMSC sheet, retaining the ECM that is deposited
beneath the monolayer during culture. As a potent regu-
lator of cell function and differentiation, the ECM can
be well preserved during cell sheet fabrication, thereby
enhancing osteoblastic differentiation and improving
bone formation. The matrix allows easy re-attachment
to CaP particles/PRP gel and additionally provides the
stability of, and osteoinduction by, CaP particles. More-
over, the growth factors released from CaP particles/PRP
gel can be localised by the BMSC sheet, further promot-
ing bone regeneration.
In this study, we hypothesised that incorporation of a
BMSC sheet along with PRP gel/CaP particles would ac-
celerate bone regeneration. We investigated the differen-
tiation of BMSCs or a BMSC sheet cultured with CaP
particles and/or PRP in vitro and the ability of PRP gel/
CaP particles combined with a BMSC sheet to promote
bone regeneration in rat femoral bone defects.
Methods
Preparation of CaP particles
CaP particles were fabricated according to the proce-
dures reported by Yurong Cai et al. [16]. Briefly, CaP
particles were synthesised by dropwise addition of
5.0 mM CaCl2 (60 ml) to 240 mL of solutions containing
1.25 mM Na2HPO4 and 24 × 10
-4 M hexadecyl (cetyl)
trimethyl ammonium bromide (CTAB) in magnetically
stirred vessels at 20 °C. The pH of the solutions was
maintained at 9.5 ± 0.5 by the addition of 0.1 M ammo-
nia. The suspension was then stirred at 20 °C for another
24 h to allow completion of particle formation. The pre-
cipitate was washed with distilled water. After drying in a
vacuum at 40 °C, solids were washed with ethanol to dis-
solve residual CTAB molecules and separated from the
CTAB by five 10-minute cycles of centrifugation at
1,800 g. The CaP particles in the precipitate were then
dried in a vacuum at room temperature. Transmission
electron microscopy (TEM, JEM-200CX, Tokyo, Japan,
operated at 160 KV) (Fig. 1a) showed that the CaP parti-
cles were sphere-like with approximate diameters of
140 nm. Figure 1b shows TEM images of CaP particles
after being ultrasonicated using an ultrasonic cell crushing
apparatus. The size distributions of the nanoparticles were
relatively narrow and the average diameter was 140 ±
24 nm (analysed by Image-Pro Plus 6.0, Media Cybernet-
ics, Yena, Germany.) (Fig. 1c). The energy dispersive spec-
trometer (EDS) analysis showed that the Ca:P ratios of the
particles was 1.67 ± 0.02. The x-ray diffraction (XRD,
Rigaku D, Tokyo, Japan/max-2550 pc, scan step of 0.02
from 10 ° to 60 °) analysis indicated that the particles were
poorly crystalline hydroxyapatite (HA) (Fig. 1d).
Preparation of PRP and PRP gel/CaP particles composite
Five Sprague-Dawley rats were used to prepare the PRP.
The Institutional Animal Care and Use Committee of
Zhejiang University approved all animal experimental
protocols. Approximately 8 mL of venous blood from
the right atrium of each rat were drawn into a sterile
tube containing sodium citrate as an anticoagulant for
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processing PRP. The platelets were enriched by a two-
step centrifugation process. During the first centrifuga-
tion at 200 × g for 10 minutes in a refrigerated centrifuge
5415R (Eppendorf Corporation, Eppendorf, Germany),
the blood components were separated into two phases:
one phase comprising PRP and the other comprising
erythrocytes and leukocytes. The samples of PRP under-
went a second centrifugation at 560 × g for 15 minutes
that allowed precipitation of the platelets, which were
then re-suspended in 20 μL of plasma. Samples of PRP
and whole blood were analysed using an automatic coun-
ter (Sysmex F-820, Sysmex Corporation, Tokyo, Japan ).
The average platelet concentration in whole blood was
2.36 ± 0.52 × 108/mL, while platelets reached an average
concentration of 13.2 ± 1.18 × 108/mL in a processed PRP,
which was six-fold the serum level.
To prepare the PRP gel, the platelets were activated
with thrombin (Sigma, St. Louis, MO USA 5 U/mL in
40 mM CaCl2): 10 μL of PRP and 10 μL of thrombin
was mixed and incubated at 37 °C for 30 minutes to
form PRP gel (Fig. 2a). The PRP gel/CaP particle com-
posite was prepared by simultaneously mixing 10 μL of
PRP and 10 μL of thrombin with 10 mg of particles.
After mixing, the composite scaffolds were incubated
at 37 °C for 30 minutes to form a strong PRP gel/CaP
particle composite [17, 18]. Then the PRP gel and PRP
gel/CaP particle composites were observed by scanning
electron microscopy (SEM).
BMSC culture, cell sheet preparation and fabrication of
cell sheet-scaffold constructs
Rat BMSCs were isolated from the bone marrow of
young adult male Sprague-Dawley rats following the
procedure described by Nakamura et al. [8] and Kaur et
al. [19]. Briefly, rats were euthanised with CO2, and the
femurs and tibias were then removed. The bones were
washed in α-minimal essential medium (α-MEM) sup-
plemented with 1 % (v/v) penicillin/streptomycin
(Gibco, Thermo Fisher Scientific Inc. New York, USA ).
Both ends of the femurs and tibias were cut away from
the epiphysis, and the bone marrow was flushed out of
the bone with 10 mL of medium in a syringe. The cells
were filtered through a 70-μm cell strainer and centri-
fuged at 300 g for 5 minutes. The cell pellet was re-
suspended in 10 mL of α-MEM supplemented with 10 %
foetal bovine serum (FBS, Gibco, Thermo Fisher Scien-
tific Inc. New York, USA) and plated in a culture plate.
Cells were maintained at 37 °C in a humidified atmos-
phere with 5 % CO2, and the medium was changed every
2 days. When adherent cells reached 80–90 % conflu-
ence, they were detached with 0.25 % trypsin-EDTA
Gibco, Thermo Fisher Scientific Inc. New York, USA)
and replanted at 1:3 in regular growth medium to allow
for continued passaging. BMSCs at passages 3–4 were
used in the experiments. Monolayer cultured cells were
detached by mechanical scratching and filtered through a
stainless-steel mesh filter to eliminate cell aggregates from
Fig. 1 a TEM images of CaP particles. b TEM of CaP particles after being ultrasonicated by ultrasonic cell crushing apparatus. c Particle size
distribution of the CaP particles. d XRD patterns of CaP particles
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the single-cell suspension. After centrifugation, cells were
blocked with 1 % bovine serum albumin for 15 minutes.
Cells were then incubated with 5 μL of antibodies
(APC-CD44, APC/Cy7-CD45, PE/Cy7-CD73, Percp/
Cy5.5-CD90 and FITC-CD105) (Biolegend, San
Diego, CA, USA) for 30 minutes on ice. Appropriate
isotype control antibodies were used to exclude non-
specific binding. After washing, the samples were
analysed using a BD FACSCalibur (BD Biosciences, San
Jose, California, USA).
To create the cell sheet, the released cells were seeded
at 4 × 104 cells/cm2 into flasks cultured in 10 mL of α-
MEM supplemented with 10 % FBS (Gibco, Thermo
Fisher Scientific Inc. New York, USA) for at least 1 week.
Cells were maintained at 37 °C in a humidified atmos-
phere with 5 % CO2, and the medium was replaced daily.
After 1 week, the layered BMSCs were formed. The cells
were then rinsed with phosphate-buffered saline (PBS;
Gibco, Thermo Fisher Scientific Inc. New York, USA)
twice, and then lifted as a cell sheet using a scraper
(Fig. 2b). The intact BMSC sheet was then wrapped
around the PRP gel/CaP particles or single CaP particles
(10 mg) for in vivo implantation (Fig. 2c).
To track the implanted BMSC sheet, first the BMSCs were
stained with chloromethyl-benzamidodialkylcarbocyanine
(CM-Dil, Molecular Probes, Thermo Fisher Scientific Inc.
New York, USA ) following the method described by
Kruyt et al. [20] (Fig. 2d). BMSCs in suspension were
washed with PBS and incubated with CM-Dil at a
concentration of 2 μg/mL PBS for 5 minutes at 37 °C and
15 minutes at 4 °C. After two washings in PBS, the cells
were re-suspended in α-MEM and cultured to form a
BMSC sheet. This fluorescent marker intercalates within
the cell membrane lipid bilayer and is useful for tracking
live cells in vivo [21, 22]. The dye does not influence cell
metabolism or viability [23].
Proliferation of BMSCs stimulated by CaP particles
Based on the particle weight to medium volume ratio,
various concentrations of particles were prepared. Con-
centrations of 0.001, 0.01, and 0.1 % of particles corre-
sponded to 0.01, 0.1, and 1.0 mg of particles per mL of
medium. The particle solutions were ultrasonicated using
ultrasonic cell crushing apparatus (SL-1000D, Nanjing
Shunliu Instrument Co. Ltd., Nanjing, China) at a fre-
quency of 20 kHz and maximum power (1000 kW) for
10 minutes in a sealed sterile container to minimise ag-
glomeration of the particles before adding them to the cell
culture. The proliferation of BMSCs plated in 96-well
plates (2 × 103 cells per well) co-cultured without (deter-
mining the positive control) or with CaP particles at con-
centrations of 0.001, 0.01, and 0.1 % was evaluated using a
3(4,5 dimethylthiazol)-2,5 diphenyltetra-zolium (MTT)
assay. The cell-free material present served as blank
samples. After culturing for 1, 3, or 7 days, the MTT assay
was performed according to the cell proliferation kit
protocol (Sigma, St. Louis, MO USA). This assay was re-
peated three times per group.
Fig. 2 a PRP was activated to form PRP gel. b, a BMSC sheet was harvested using a cell scraper. c The PRP gel/CaP particles composite
was wrapped by BMSC sheet. d BMSCs were stained by CM-Dil. e Bone defects were prepared in the cortical bone of femurs. f BMSC
sheet/PRP gel/CaP particle composite was implanted into bone defects
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Differentiation of BMSCs cultured with CaP particles and/
or PRP in vitro
The differentiation of BMSCs or a BMSC sheet cultured
without (the control group) or with CaP particles
(0.001 %) and/or PRP for 7 days was examined by evalu-
ating the expression levels of the genes encoding colla-
gen type I, osteocalcin, collagen III, tenomodulin and
VEGF. To assess osteogenic differentiation, BMSCs were
seeded in a six-well plate at a density of 2 × 105 per well;
each BMSC sheet was cultured in osteogenic medium
consisting of α-MEM supplemented with 10 mM Na-β
glycerophosphate, 0.2 mM ascorbic acid, and 10-8 M dexa-
methasone (Sigma, St. Louis, MO USA).
For non-osteogenic differentiation, BMSCs were seeded
in a six-well plate at a density of 2 × 105 per well; the
BMSC sheet was then cultured in α-MEM. Particle sus-
pensions or PRP (10 μL) with particle suspensions were
added to cells to a particle concentration of approximately
0.01 mg/mL (0.001 %). As controls, cells were subjected to
the same manipulations but incubated in the absence of
particles or PRP.
Moreover, after culturing without or with CaP particles
(0.001 %) and/or PRP for 14 days, the osteogenic differ-
entiation of the BMSCs was examined by means of Ali-
zarin red staining quantification and alkaline
phosphatase (ALP) quantification. The ALP activity of
BMSCs was determined using a pNPP Phosphatase
Assay kit (Nanjing Jiancheng Bio-engineering Co., Ltd.
Nanjing, China). ALP activity was normalised to the
total protein content determined using a bicinchoninic
acid (BCA) assay. For Alizarin red staining quantifica-
tion, the Alizarin red stain was dissolved in 500 μL of
5 % SDS/HCl (m/v, HCl = 0.5 M) solution. Half an hour
later, the absorbance of the solution at 405 nm was de-
termined using a microplate reader. A Cell Counting
Kit-8 (CCK-8) was used to assess BMSCs proliferation
after culturing without or with CaP particles (0.001 %)
and/or PRP for 14 days. The quantification of Alizarin
red staining per cell was determined by dividing the op-
tical density (OD) value of Alizarin red by that of CCK-8
staining.
Calcein blue (C15H15NO7) has been administered by
intraperitoneal injection to label newly calcified tissues
in vivo. In the present study, we used calcein blue to
label newly mineralised nodules in vitro. Calcein blue
powder (Sigma, St. Louis, MO USA) was dissolved in
100 mM KOH (diluted in distilled water) and filtered to
create the 30 mM stock solution. Following culture of
BMSCs without or with CaP particles (0.001 %) and/or
PRP for 14 days, 30 μM (the final concentration in cul-
ture medium) calcein blue was added to the medium
and incubated overnight. Prior to microscopic examin-
ation and photography, cultures received fresh
medium without fluorochrome to prevent generation
of a non-specific fluorescent background. Calcein blue
emits blue fluorescence that can be detected using a Sap-
phire green fluorescent protein (GFP) filter.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR) assays for cultured BMSCs, in vitro
fabricated BMSC sheets, and particles and/or
PRP-induced BMSCs
Total cellular RNA was extracted from cells with indicated
treatments using TRIzol reagent (Invitrogen Thermo
Fisher Scientific Inc. New York, USA ). Complementary
DNAs (cDNAs) were synthesised using a commercial kit
(SuperScript II Reverse Transcriptase, Invitrogen, Thermo
Fisher Scientific Inc. New York, USA ) according to the
manufacturer’s recommendations. Each group involved
four wells. Real-time polymerase chain reaction (PCR)
quantification was performed using the SYBR Premix Ex
Taq Kit (TaKaRa, Tokyo, Japan) on an iQTM5 multiplex
real-time fluorescence quantitative PCR instrument (Bio-
Rad, California, USA). The gene expression levels of
osteocalcin (OCN), collagen I, collagen III, tenomodulin,
and VEGF were determined, following the procedures de-
scribed by Nakamura et al. [8] and Kaur et al. [19]. Ther-
mal cycle conditions comprised 1 minute at 95 °C for
activation of the Universal mixture AmpliTaq Gold Poly-
merase, followed by 45 cycles of 10 s at 95 °C for denatur-
ing and 25 s at 62 °C for annealing and extension. Primers
for target genes and the internal control gene are listed in
Table 1. 18S rRNA was used as an internal control to ad-
just for differences between samples.
Animals and surgical procedure
Eighteen 12-week-old male Sprague-Dawley rats (weigh-
ing about 300–400 g each) were used in this study. The
Institutional Animal Care and Use Committee of
Zhejiang University approved all animal experimental
protocols. According to the procedures of a previous
study [24], under anaesthesia induced with an intraperi-
toneal injection of 8 % chloral hydrate (400 mg/kg body
weight), femoral bones were carefully exposed by exfoli-
ation. After the periosteum was dissected, artificial bone
cavities with 2.5 and 5.0 mm transverse and longitudinal
extensions were prepared in the cortical bone of both fe-
murs by drilling with a round bur attached to a dental
hand piece (Fig. 2e). The bone cavity was carefully and
completely washed prior to insertion of bone marrow
cells.
Thirty-six bone defects were randomly divided into six
groups (n = 6/group). The bone defects were either un-
treated or treated with BMSCs/PRP gel, CaP particles
(10 mg), PRP gel/CaP particles, BMSC sheet/CaP parti-
cles, or a BMSC sheet/PRP gel together with CaP parti-
cles (Fig. 2f ). The rats were euthanized 4 weeks after
surgery. Fifteen additional mice with bone defects
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implanted with the CM-Dil-labelled BMSC sheet/PRP
gel/CaP particles were sacrificed at 1 day, 3 days, 7 days,
2 weeks and 4 weeks after surgery. The femurs were im-
mediately dissected from the rats at 1 day, 3 days, 7 days,
2 weeks and 4 weeks after surgery, and the bone samples
were examined using a small animal in vivo fluorescence
imaging system (Maestro, MA, USA). For confocal laser
scanning microscopy (CLSM, LSM 510, Zeiss, Yena,
Germany) observation, the samples were fixed in neutral
buffered formalin, decalcified and placed into a 0.1-mol/
L phosphate buffer solution containing 30 % sucrose for
48 h at 4 °C and embedded into optimum cutting
temperature compound (OTC). Sagittal plane sections
(4 μm) were cut using a frozen sectioning machine
(Lecia, Wetzlar, Germany). The images were obtained
after staining of the sections with Hoechst 33258
(Sigma, St. Louis, MO USA).
Gross observation and radiological examination
Postoperative activities, food intake, and wound healing
were evaluated in the animals. The animals were eutha-
nized, after which bone repair and callus growth were
evaluated using samples collected through the original
incision. Anterior–posterior radiographs of the bilateral
femur were obtained to assess bone healing at 4 weeks
after implantation.
Histological examination and histomorphometric analysis
Specimens from the bone defect sites were fixed in 10 %
paraformaldehyde (Shanghai Biological Engineering Co.,
Ltd., Shanghai, China), decalcified with formate-sodium
formate, and embedded in paraffin. Sagittal plane sec-
tions (7 μm) from each defect were prepared, stained
with haematoxylin and eosin, and examined under a
light microscope (Olympus, Tokyo, Japan). For
histomorphometric analysis, five sequential sections per
sample were selected for evaluation under low magnifi-
cation, allowing coverage of the entire defect. Using the
image analytical software Image-Pro Plus, all slides were
examined by two independent observers to identify the
type of bone tissue. The extent of bone formation was
indicated by the percentage of bone tissue area within
the cortical bone defect site, and an average value was
calculated for each sample.
Statistical analysis
Results were analysed by one-way analysis of variance
and are expressed as means and standard deviations.
Data analyses were performed using the SPSS software
(ver. 15.0; SPSS, Inc., Chicago, IL, USA). Tukey’s test
was used for multiple comparisons, and the level of sig-
nificance was set at P <0.05.
Results
Flow cytometry
On flow cytometry results the cultured cells expressed
CD44, CD73, CD90, and CD105 but not CD45, which is
characteristic of BMSCs (Fig. 3).
SEM observation
After the CaP particles were fabricated, they were ob-
served by SEM. Figure 4a shows the round shape of the
CaP particles, which tended to agglomerate. After the
PRP gel and PRP gel/CaP particles were incubated at
37 °C for 30 minutes, and lyophilized in a freeze dryer
(Heto Power Dry LL1500), the PRP gel and PRP gel/CaP
particle composites were observed by SEM (Fig. 4b, c).
The polymerisation of the PRP gel formed a complex
network of fibres (Fig. 4b). The PRP fibres partially cov-
ered the surface and penetrated the microstructure of
Table 1 Nucleotide primers used for qRT-PCR
Genes Oligonucleotide sequence(5′-3′) Product size (bp)
18S rRNA Forward: GAATTCCCAGTAAGTGCGGGTCATA 105
Reverse: CGAGGGCCTCACTAAACCATC
Collagen type I Forward: TGGCCAAGAAGACATCCCTGAAGT 81
Reverse: ACATCAGGTTTCCACGTCTCACCA
Osteocalcin Forward: CTCACTCTGCTGGCCCTGAC 111
Reverse: CACCTTACTGCCCTCCTGCTTG
Collagen III Forward: GTGTCTGCGACTCGGGATCT 120
Reverse: TAGAAGGCTGTGGACATATTGCA
Tenomodulin Forward: GGACTTTGAGGAGGATGGTGAA 83
Reverse: GGACCACCCATTGCTCAT TC
Vascular endothelial growth factor Forward: GTCACCACCACACCACCATCGT 76
Reverse: CTCCTCTCCCTTCATGTCAGGCT
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the CaP particles; the particles were connected to each
other through the PRP fibres (Fig. 4c). After the PRP
gel/ CaP particles formed, then the intact BMSC sheet
was then wrapped around the PRP gel/CaP particles or
single CaP particles and the composites were incubated
at 37 °C in a humidified atmosphere with 5 % CO2 for
2 h. After fixation and dehydration, the composites were
observed by SEM. The BMSC sheet wrapped around the
particles and the shape of the cells could be seen
(Fig. 4d). The BMSC sheet completely wrapped the sur-
face of the PRP gel/CaP particle composite (Fig. 4e). The
cells juxtaposed tightly together and formed dense cell
layers.
BMSC proliferation
A decrease in BMSC proliferation for particle
concentrations greater than 0.001 % was observed
compared to the control (P <0.05) (Fig. 5a). There
was a dose-dependent effect; i.e., the highest concen-
tration resulted in the greatest inhibition of BMSC
proliferation.
Analysis of gene expression
After BMSCs or a BMSC sheet cultured without or with
CaP particles (0.001 %) and/or PRP for 7 days, gene ex-
pression was detected. The expression of the collagen
type I and osteocalcin genes in BMSCs and the BMSC
sheet treated with CaP particles was notably upregulated
compared to that of the controls (P <0.05). The expres-
sion levels of the collagen type I and osteocalcin genes
of BMSCs alone and BMSCs treated with CaP particles
and PRP were significantly higher than those of CaP par-
ticles and the control group (P <0.01) (Fig. 5b, c). In
addition, PRP promoted collagen III and tenomodulin
gene expression in BMSCs and the BMSC sheet (Fig. 5b,
c). The BMSC sheet was associated with greater expres-
sion of the VEGF, collagen I, and osteocalcin genes than
were cultured BMSCs (P <0.05) (Fig. 5d).
Alizarin red staining, ALP and alizarin red staining
quantification
The alizarin red staining was increased in BMSCs co-
cultured with CaP particles/PRP compared to CaP
Fig. 3 Flow cytometry results for BMSCs, expressing CD44, CD73, CD90 and CD105, but not CD45. Red histogram is the negative control. Left side
of the blue histogram (in the negative control part) represents the negative expression of CD marker; right side represents the positive expression
of CD marker
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particles or controls (Fig. 5e-g). A calcification node
formed, indicating that the CaP particles and PRP syner-
gistically induced osteogenic differentiation of BMSCs.
The alizarin red staining in the controls was considerably
weaker.
At 14 days, the ALP activity was 3.01 ± 0.51 nmol/s/mg
protein in cells co-cultured with CaP particles/PRP,
which was significantly higher than 1.95 ± 0.36 nmol/s/
mg protein for cells co-cultured with CaP particles and
0.79 ± 0.08 nmol/s/mg protein for BMSCs in the control
group (P <0.05) (Fig. 5h).
Alizarin red staining quantification also showed that
BMSCs co-cultured with CaP particles/PRP had the
highest expression (0.84 ± 0.07), significantly higher than
that of the cells combined with CaP particles (0.4 ± 0.06)
and the controls (0.09 ± 0.01) (P <0.05) (Fig. 5i).
On calcein blue stained images there was little
fluorescence in the control group (Fig. 5j). The for-
mation of mineralised nodules marked by calcein blue
was clearly demonstrated by an increase in both the
area and intensity in BMSCs co-cultured with CaP
particles or with PRP (Fig. 5k, l). The mineralised
nodule staining pattern of calcein blue fluorescent im-
ages was in agreement with the Alizarin red staining
pattern.
Tracking of implanted BMSC sheet/PRP gel/CaP particles
Red fluorescence in the bone defect zones was visualised
using a small animal in vivo fluorescence imaging system
after implantation at 1 day, 3 days, 7 days, 2 weeks, and
4 weeks, which confirmed the presence of the implanted
BMSCs (Fig. 6a–e). After frozen sectioning, red fluores-
cence was also visible in the defect zones by confocal
microscopy (Fig. 6f–j). However, the fluorescence inten-
sity gradually weakened.
Gross observation
All rats ate a normal diet and behaved appropriately
after surgery, and all survived until euthanasia with no
apparent complications, such as incision infection or
skin necrosis. At 4 weeks, in the control group, the bone
defect sagged inwards and a thin layer of bone covered
the defects, which distinguished them from normal bone
tissue (Fig. 7a). In the BMSCs/PRP group, the bone de-
fect was covered by a thin layer of bone, which was also
distinguished from normal bone tissue (Fig. 7b). A large
part of the defect in the CaP particle group was filled
with CaP particles and could be recognised from the
surface (Fig. 7c). In the CaP particles/PRP gel group, the
surface of the defects was filled with thin bone tissue
and few particles (Fig. 7d). In the BMSC sheet/parti-
cles group and the BMSC sheet/particles/PRP gel
group, bone defects were regenerated with dense bone
tissue (Fig. 7e, f ). However, in the BMSC sheet/par-
ticle group, the bone tissue in the middle of the bone
defect was much thinner. The defects in the BMSC
sheet/particles/PRP gel group were indistinguishable
from normal bone tissue (Fig. 7f ).
Fig. 4 Scanning electron microscopy of CaP particles (a), PRP gel (b), PRP gel/CaP particles (c), BMSC sheet-wrapped CaP particles (d) and BMSC
sheet-wrapped PRP gel/CaP particles composite (e)
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Radiographic examination
X-ray images were obtained at 4 weeks after surgery to
evaluate bone healing within defects. Small portions of
the bone defect had not regenerated in the control
group (Fig. 7g). Thin bone tissue was regenerated in the
BMSCs/PRP group (Fig. 7h). In the particles group, the
defects were mostly filled with non-degraded particles
(Fig. 7i). Bone tissue was regenerated in the CaP parti-
cles/PRP gel group and the BMSC sheet/CaP particle
group (Fig. 7j, k). The bone tissue in the CaP particles/
PRP gel group was much thinner than that of the BMSC
sheet/CaP particles group. Finally, the cortical bone tis-
sue had completely regenerated in the BMSC sheet/PRP
gel/CaP particles group (Fig. 7l).
Histological analysis
In the control group, much thinner woven bone tissue
bridged the bone defects. However, some fibrous tissue
had filled the surface of the regenerated bone tissue
(Fig. 8a, b). In the BMSCs/PRP gel group, a quantity of
woven bone filled the bone defects and the bone tissue
was much thinner in the middle of the defects (Fig. 8c, d).
In the CaP particles group, woven bone had formed at the
edge of the defects, whereas other parts of the defects
were filled with fibrous tissue and CaP particles. Some
particles were surrounded by fibrous tissues and were out-
side the defects, due to the instability of the particles
(Fig. 8e, f ). In the CaP particles/PRP gel group, some
woven bone filled the bone defects (Fig. 8g, h). In the
(See figure on previous page.)
Fig. 5 a Dose effects of CaP particles on BMSC proliferation after culturing for 1, 3 and 7 days (mean ± SD) (*P <0.05). b Gene expressions of BMSC
sheet cultured with CaP particles or/and PRP for 7 days (*P <0.05). c Gene expressions of BMSCs cultured with CaP particles or/and PRP for 7 days
(*P <0.05). d Osteocalcin, collagen I and vascular epithelial growth factor (VEGF) gene expression of the BMSC sheet and cultured BMSCs (*P <0.05). e,
f, g The alizarin red staining of BMSCs cultured with PRP/CaP particles, CaP particles or without treatment for 14 days. e The alizarin red staining in the
controls was much weaker. f The alizarin red staining was increased when treated with CaP particles. g A calcification node formed in the BMSCs
co-cultured with CaP particles/PRP. h ALP activity of BMSCs cultured with PRP/CaP particles, CaP particles or without treatment for 14 days; ALP activity
was 3.01 ± 0.51 nmol/s/mg protein, 1.95 ± 0.36 nmol/s/mg protein and 0.79 ± 0.08 nmol/s/mg protein in the CaP particles/PRP group, CaP particles
group and control group respectively. i: Quantification of alizarin red staining of BMSCs cultured with PRP/CaP particles, calcium phosphate particles or
without treatment for 14 days; expression of BMSCs co-cultured with CaP particles/PRP was 0.84 ± 0.07, the cells with CaP particles was 0.4
± 0.06 and the control was 0.09 ± 0.01. j, k, l Calcein blue staining of BMSCs without treatment (j) or cultured with CaP particles (k) or
PRP/CaP particles (l) for 14 days
Fig. 6 Fluorescence images obtained by a small animal in vivo fluorescence imaging system at 1 day (a), 3 days (b), 7 days (c), 2 weeks (d), 4 weeks
(e) after the bone defects were treated with CM-Dil-labelled BMSC sheet/PRP gel/CaP particles. Red fluorescence in the bone defect zones was
visualised using a small animal in vivo fluorescence imaging system, which confirmed the presence of the implanted BMSCs. After further frozen
sectioning, red fluorescence was also visible in the defect zones by confocal microscopy at 1 day (f), 3 days (g), 7 days (h), 2 weeks (i) and 4 weeks (j).
However, the fluorescence intensity gradually weakened. The red and the blue colours were stained by CM-Dil and Hoechst 33258, respectively
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BMSC sheet/CaP particles group, the defects were regen-
erated with cortical bone tissue, which was much thinner
than normal cortical bone, especially in the middle of the
defect (Fig. 8i, j). In the BMSC sheet/PRP gel/CaP particle
group, the defects were filled with well-distributed and
thick cortical bone tissue (Fig. 8k, l). The shadow of parti-
cles was obvious and the particles were regenerated with
new bone tissue.
Histomorphometric analysis
At 4 weeks, the area of regenerated bone tissue in the
BMSC sheet/PRP gel/CaP particle group was signifi-
cantly greater (87 ± 8.2 %) than that in the other five
groups (P <0.05) (Fig. 9). In addition, the area of regen-
erated bone in the BMSC sheet/CaP particle group (71
± 3.6 %) was significantly greater than that of the control
group (39 ± 4.7 %), the BMSCs/PRP group (48 ± 3.4 %),
the CaP particle group (29 ± 5.1 %), and the CaP parti-
cles/PRP gel group (45 ± 3.8 %) (P <0.05). No significant
difference in the area of bone tissue was observed
among the control group, the CaP/PRP gel group, and
the BMSCs/PRP group; all had greater values than did
the CaP particle group.
Discussion
The results of this study demonstrated that incorpor-
ation of a BMSC sheet along with PRP gel/CaP particles
greatly promoted bone regeneration. The BMSC sheet
and PRP gel can provide cells and growth factors to ac-
celerate bone formation. Moreover, we revealed that the
BMSC sheet/CaP particles also had a significant positive
effect on bone formation, compared to CaP particles/
PRP gel and CaP particles.
This in vitro study demonstrated that CaP particles
have dose-dependent effects on BMSC proliferation.
BMSC proliferation was decreased by addition of 0.1 %
and 0.01 % CaP particles compared to the control group,
which was consistent with the results of a previous study
[25]. Based on the cell proliferation assay, the appropri-
ate concentration of CaP particles (0.001 %) was then
Fig. 7 Gross observation and radiographic analysis of repaired bone defects at 4 weeks after surgery. a and g Control group. b and h BMSCs/PRP
gel group. c and i CaP particles group. d and j PRP gel/CaP particles group. e and k BMSC sheet/CaP particles group. f and l BMSC sheet/PRP
gel/CaP particles group
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used to evaluate their effect on induction of osteogenic
differentiation of BMSCs and a BMSC sheet. BMSCs
and BMSC sheets co-cultured with CaP particles
(0.001 %) highly expressed osteocalcin and collagen type
I genes, and exhibited positive alizarin red staining and
ALP activity, which indicated osteogenic differentiation.
Moreover, CaP particles combined with PRP exerted a
synergistic effect on the osteogenic differentiation of
BMSCs and BMSC sheets. The osteocalcin and collagen
type I genes of BMSCs and BMSC sheets were highly
upregulated, alizarin red staining was highly positive,
and the alizarin red staining intensity and ALP activity
were highest. PRP contains several growth factors, in-
cluding PDGF, TGF-β1, and VEGF, which can induce
osteogenic differentiation of BMSCs. Mouse BMSCs
treated with PRP had greater ALP activity and collagen
type I gene expression [26]. However, the specific growth
factors in PRP were not quantified in this study. A previ-
ous study reported that the levels of growth factors
(PDGF, TGF-β1 and VEGF) in PRP samples from goats
were significantly higher than those of circulating plasma
and the osteogenic differentiation of BMSCs was pro-
moted by PRP [27]. Zhou et al. [28] reported that the
addition of PRP had a synergistic effect on osteogenic
differentiation of BMSCs, which was consistent with our
results.
Moreover, previous studies also showed that PRP in-
duces tenogenic differentiation of adult stem cells in
vitro [29–31] and PRP combined with adult stem cells
promote tendon repair in vivo [32, 33]. PRP can pro-
mote tenogenic differentiation and increase expression
of such tenocyte-related genes as collagen type I, colla-
gen type III, tenomodulin [29–31], in agreement with
our results. As shown in the study, PRP promoted colla-
gen III and tenomodulin gene expression by BMSCs and
BMSC sheets in vitro.
Basic research has demonstrated the ability of PRP to
promote bone healing [34, 35]. In this study, the PRP
gel/CaP particle group and the PRP gel/BMSCs group
had greater bone formation than did the CaP particle
group. CaP particles mediated osteoconduction. In the
absence of the PRP gel, the bone rested directly on
the particle surface. Immediately after implantation,
contact with biological fluids induces dissolution of
the CaP material, leading to precipitation of the bio-
logical apatite. CaP particles, in fact, serve as scaffold-
ing that allows new bone to progress from the
periphery to the centre of the implant. PRP can be
activated by the addition of thrombin in the presence
of calcium chloride and a formed PRP gel. Thrombin
activation of PRP causes the release of growth factors,
which can improve vascularity and promote tissue
(See figure on previous page.)
Fig. 8 Histological examination of the repaired bone tissues at 4 weeks after implantation. a and b Control group. c and d BMSCs/PRP gel group.
e and f CaP particles group. g and h PRP gel/CaP particles group. I and j BMSC sheet/CaP particles group. k and l BMSC sheet/PRP gel/CaP
particles group. b, d, f, h, j, l higher magnifications of a, c, e, g, i, k respectively. w woven bone tissue, c cortical bone tissue, f fibrous tissue.
Arrow residual particles. Scale bar 300 μm
Fig. 9 Extent of bone formation was expressed as a percentage of bone tissue area within the original cortical bone defect area. Error bars
represent means ± SD (n = 5); *P <0.05; #CaP/BMSC sheet vs CaP/PRP, CaP, BMSCs/PRP, Control, P <0.05; $CaP/PRP/BMSC sheet vs other five
groups, P <0.05
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regeneration [36, 37]. In addition, use of PRP gel in
defects may facilitate release of growth factors by
PRP into the immediate local environment and possibly
maintain the slow release of these factors [38]. The PRP
seemed to modify and promote this standard osteocon-
duction phenomenon: the newly formed bone almost al-
ways grew at a distance from the surface of the granules.
The release of growth factors from PRP gel may be highly
beneficial for enhancing BMSCs proliferation and differ-
entiation, thus promoting bone regeneration in vivo. How-
ever, owing to the limited effect of PRP and low
degradability of CaP particles, the effect on bone regener-
ation was not significantly superior to that of the control
group and the BMSCs/PRP gel group.
BMSCs are multipotential cells that play essential roles
in bone regeneration. The BMSC sheet has proven ef-
fective in bone formation [8] and can effectively preserve
cell–cell contact and the extracellular matrix (ECM).
Furthermore, the layered cell sheet may mimic the in
vivo deposition of bone matrix where osteoblasts are at-
tached on the mineralised sheet [39]. Moreover, the
BMSC sheet expresses an osteogenic gene (osteocalcin)
and angiogenic gene (VEGF) at high levels and may act
as periosteum to promote bone regeneration. Therefore,
the BMSC sheet/CaP particles group exhibited more ex-
tensive osteogenesis than did the control group, the CaP
particles group, or the CaP particles/PRP gel group,
which was consistent with a previous report [40] that
the effect of BMSCs in bone regeneration was superior
to that of PRP. The defects in the BMSC sheet/CaP par-
ticles group were regenerated with cortical bone tissue.
However, in the control group, BMSCs/PRP gel group,
and the CaP particles/PRP gel group, woven bone tissue
filled the defects.
Owing to the positive effect of PRP and the BMSC
sheet on osteogenesis and angiogenesis, the combination
of PRP gel/CaP particles with a BMSC sheet induced the
strongest bone regenerative response and greatly acceler-
ated bone regeneration compared with other groups.
The BMSC sheet/PRP gel/CaP particles group showed
well-distributed and thick cortical bone tissue. This is
the first report, to our knowledge, of effective transplant-
ation of a BMSC sheet with PRP gel/CaP particles to pro-
mote bone regeneration. A previous study showed that
BMSCs in association with PRP lead to more rapid bone
regeneration and remodelling [34]. Preliminary clinical re-
sults showed that transplantation of BMSCs and PRP was
effective during distraction osteogenesis [41].
Vascularisation can enhance bone regeneration by ac-
celerating the differentiation and/or maturation of infil-
trating osteoblasts and osteoblast precursor cells during
development of new bone. The BMSC sheet/PRP gel/
CaP particle group showed obvious osteogenesis, which
could be the result of neovascularisation mediated by
the BMSC sheet and PRP [42]. PRP is composed of
many growth factors known for their proliferative, differ-
entiative and chemo-attractive effects on various cells,
which can induce the recruitment of resident stem/pro-
genitor cells or mature cells participating in the develop-
ment of tissue-engineered bone in vivo. In vitro results
showed that PRP could induce the expression of pro-
angiogenic factors (VEGF) by BMSCs and the BMSC
sheet. These results indicate that PRP induces the secre-
tion of VEGF by BMSCs and BMSC sheet in vitro, which
possibly allows the specific recruitment and proliferation
of endogenous endothelial cells participating in blood
vessel formation in vivo. In addition, the BMSC sheet
also highly expressed the VEGF gene. It is possible that
the BMSC sheet can self-regulate the secretion of these
pro-angiogenic proteins. Therefore, the direct and para-
crine effect of the implanted BMSC sheet and the effect
of cell adhesion and host cell recruitment of PRP syner-
gistically contributed to vascularization and bone healing
[42]. The vascularization facilitates delivery of oxygen
and nutrients to the construct and increases the volume
of tissue-engineered bone. Furthermore, signals from
newly formed vessels may enhance the osteogenic poten-
tial of the BMSC sheet, which ultimately influences the
maturation of tissue-engineered bone. These results in-
dicate that the BMSC sheet/PRP gel/CaP particles are
effective for repair of bone defects.
The effectiveness of any cellular repair approach de-
pends on the retention of cell viability after implant-
ation. In this study, CM-Dil was used to track the
transplanted BMSC sheet, and confirmed that the trans-
planted BMSCs were alive and localised within the de-
fects. Detailed analysis of the tissue sections showed that
the red dots were distributed within the defect zone.
Therefore, we demonstrated that the implanted BMSCs
differentiated into osteoblasts, thereby enhancing the
healing of bone defects. However, the contribution of
the host cells cannot be excluded. Confocal microscopy
showed that not all cells present in the defect were
labelled. Therefore, the host cells had already migrated
into the defect site and could have contributed to bone
regeneration, as was seen in the control group. However,
the self-regenerated bone tissue was thinner, woven bone
tissue. In addition, a small amount of fibrous tissue filled
the surface of the regenerated bone tissue.
The results of the present study indicate that the im-
planted BMSC sheet and PRP played important roles in
promoting bone regeneration. Autologous cell therapy
for bone regeneration by combining BMSCs with PRP
has many clinical advantages. First, BMSCs can be ex-
panded by cell culture, thus creating a cell sheet. Second,
the preparation of the BMSC sheet was simple and re-
quired only a culture flask. In clinical cases, a relatively
large volume of fresh bone marrow can be harvested or
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the number of cells expanded by serial passaging. A
certain number of such sheets would be able to cover
the greater cross-sectional dimensions of human bones.
Third, PRP can be easily extracted from autologous
blood and activated to form a PRP gel. The procedure is
simple and safe with minimal side effects because both
BMSCs and PRP are autologous, nontoxic, and nonim-
munoreactive. The technique we proposed may be ap-
plicable for the repair of bone defects, and could be a
useful alternative to allogenic or autologous bone grafts
in this regard.
One weakness of the present study was that mechan-
ical tests were not performed. In our study, the bone
defects were almost completely regenerated with woven
or cortical bone tissue, and the differences between the
non-repaired defect area/total cortical bone area among
the six groups at four weeks after surgery were not obvi-
ous. Derek et al. [43] investigated the effect of different
sizes of cortical bone defects on the torsional properties
of the distal femur. There was no statistically significant
difference in the torque at failure among the 17, 33, and
50 % defects. In a study by Edgerton et al. [44], circular
defects that spanned 10–60 % of the bone diameter were
created in paired sheep femurs, which were then loaded
to failure. The results showed that small defects (10 %)
of the bone diameter caused no significant torsional
strength reduction. Defects between 20 and 60 % of the
bone diameter decreased strength linearly as a function
of defect size. Regarding the length of defects, Elias [45]
investigated rectangular defects in the posterior cortex
of the femur mid-diaphysis using a finite element (FE)
model. The results showed that defects with a length of
one diameter of bone or shorter had little influence on
the femur torsional stiffness or the femur shear-stress
distribution. Therefore, the differences in the mechanical
test among groups may not be significant. However, if
the defects had been segmental bone defects, the mech-
anical test results would have been more significant. Fur-
ther studies should involve mechanical testing of
segmental bone defects of rats repaired using BMSC
sheet/PRP gel/CaP particles.
Conclusions
CaP particles combined with PRP can synergistically
stimulate osteogenic differentiation of BMSCs in osteo-
genic culture medium. Incorporation of a BMSC sheet
along with PRP gel/CaP particles greatly promotes bone
regeneration. Such a BMSC sheet and tissue engineering
strategies offer therapeutic opportunities to treat bone
defects.
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